Disclosure
All faculty participating in a continuing medical education program sponsored by Potomac Center for Medical Education are required to disclose to the sponsor and the meeting audience any real or apparent conflict(s) of interest related to the content of their presentation.
Marc C. Hochberg, MD, MPH
Disclosure Statement (March 2005)
Current Research Support
- Arthritis Foundation
- Department of Veterans Affairs
- GlaxoSmithKline
- National Institutes of Health
- Novartis Pharmaceuticals
Consultant
- Amgen
- Arakis Limited
- Astra-Zeneca Pharmaceutical Co.
- Bristol-Myers Squibb
- Genzyme Corporation
- GlaxoSmithKline
- Merck & Co., Inc.
- Merckle GmbH
- NicOx S.A.
- Novartis Pharmaceuticals Corporation
- NPS Pharmaceuticals
- Pfizer Pharmaceutical Co.
- Roche Pharmaceuticals
- Sanofi-Aventis Pharmaceutical Co., Inc.
- Takeda Pharmaceuticals North America, Inc.
- Wyeth Pharmaceuticals, Inc.
Member/Chair of DSMB
- GlaxoSmithKline
- Immunomedics, Inc.
- La Jolla Pharmaceutical Co.
- Proctor & Gamble Pharmaceuticals
- Scios, Inc.
Henry G. Bone, MD
Disclosure Statement (June 2005)
Dr. Bone is an officer and/or director of the Michigan Consortium for Osteoporosis and the Paget Foundation. These nonprofit organizations receive funding from industrial sources, but Dr. Bone receives no personal compensation from either organization.
Dr. Bone has received honoraria from presentations that were directly or indirectly supported by GSK/Roche and Merck.
Dr. Bone has received research funding or acted as a consultant to the following companies:
- Amgen
- DebioPharm
- Eli Lilly
- GSK/Roche
- Merck
- Nordic Bioscience (Sanos)
- Novartis
- NPS Pharma
- Osteologix
- Pfizer
- ProSkelia
- Zelos
Dr. Bone will be discussing non-FDA approved uses of pharmaceutical products or medical devices in his presentation, particularly the use diuretics for hypercalciuria.
